#USA #Q3 2025 #Milford #Waters Corporation #NYSE WAT

Waters Corporation Third Quarter 2025 Financial Overview

Waters Corporation (NYSE: WAT) has disclosed an impressive financial report for the third quarter of 2025, indicating notable growth in its sales and earnings metrics. The company achieved total sales of $800 million, which not only exceeded analysts' expectations but also represents an 8% increase compared to the same period last year, after adjusting for currency fluctuations.

Key Highlights of Q3 2025 Financial Results

1. Sales Performance: The reported sales of $800 million show a strong trajectory, reflecting both constant currency growth of 8% and highlighting the performance improvements within its various product segments.
2. Earnings Figures: In terms of earnings, the GAAP earnings per share (EPS) stood at $2.50, down slightly from $2.71 in Q3 of 2024. However, the non-GAAP EPS rose to $3.40, marking an impressive 16% growth from $2.93 year-over-year.
3. Product Segments Growth: The company’s instruments segment showed a 6% growth, predominantly driven by new liquid chromatography-mass spectrometry innovations. Furthermore, revenue from chemistry products surged, mainly due to the new Affinity bioseparation columns, which have been well-received by customers.
4. Recurring Revenue: Recurring revenue increased by 9% in constant currency terms, demonstrating the company’s continued strength in its service and consumables offerings, reaffirming its market leadership.
5. Pharmaceutical Sector Growth: The pharmaceuticals market witnessed an 11% growth, fueled by a broad expansion encompassing all geographic regions, particularly emphasizing the strength in the Americas.

Executive Insights

Dr. Udit Batra, President and CEO of Waters Corporation, expressed pride in the team's performance, underlining the strategic push behind their diverse product portfolio. He noted that the pharmaceutical market is currently experiencing a significant instrument replacement cycle, enabling Waters to capture considerable market opportunities.

"Our commitment to innovation continues to drive our success. The high demand for our new product lines, especially within the bioanalytical characterization space, demonstrates our ability to cater to evolving customer needs effectively," Batra stated.

The advancements seen in the Xevo™ Charge Detection Mass Spectrometer were particularly highlighted, showcasing cutting-edge technology that requires significantly less sample volume compared to traditional methods and provides expedited results.

Increased Financial Guidance

Reflecting on the strong financial performance and market position, Waters Corporation has increased its full-year 2025 sales growth forecast to a range of 6.7% to 7.3% in constant currency. This adjustment aligns with the anticipated solid performance in the upcoming quarters, underpinned by strategic growth initiatives and continued technological advancements.

Looking towards Q4 2025, the company forecasts constant currency sales growth between 5.0% and 7.0% and a non-GAAP EPS in the range of $4.45 to $4.55, indicating an expected year-on-year growth of about 9% to 11%.

Conclusion

As Waters Corporation moves forward, its trajectory appears robust, driven by the soaring demand in both its established and innovative product lines. The increased sales guidance and positive earnings reports solidify its standing in the competitive landscape of analytical instruments and science solutions. The company remains committed to maintaining its innovation-led approach, which has historically shaped its success in the global market.

For those interested in more detailed insights regarding Waters Corporation's financials, a more exhaustive report and supporting documents are available on their Investor Relations section on their official website.

• ---

Note: All financial figures reported are subject to adjustments and are reflective of the recent fiscal outcomes as of September 27, 2025.